InsidersTradesSigma
Track the MapLight Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Market capitalisation: €1.7bn. The latest transaction was reported on 25 June 2026 (Attribution). Among the most active insiders: Babler Martin. Every trade is openly available.
Analysts rate MapLight Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$39.55.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
6 of 6 declarations
MapLight Therapeutics, Inc. is a company focused on developing innovative therapies for the treatment of neurological diseases. It is listed on NASDAQ under the ticker XNAS.